Paper15123775
CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses?
Gumperz JE. J Leukoc Biol, 2004. Cited by 23 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? Papers, record 15123775. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15123775
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses?
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, CD1 | Major topic |
| Interleukin-12 | Major topic |
| Killer Cells, Natural | Major topic |
| Myeloid Cells | Major topic |
| Neoplasms | Major topic |
| T-Lymphocyte Subsets | Major topic |
| Animals | |
| Antigens, CD1d | |
| Autoantigens | |
| Cytotoxicity, Immunologic | |
| Humans |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 HL071590 | NHLBI NIH HHS | United States | R01HL071590 | PubMed and NIH |
| R01 HL 071590-01 | NHLBI NIH HHS | United States | R01HL071590 | PubMed and NIH |
Source NIH RePORTER
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,538,574 | Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. | Nat Commun | 2024 | https://conductscience.org/library/papers/38538574 | PubMed |
| 38,105,958 | Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. | medRxiv | 2023 | https://conductscience.org/library/papers/38105958 | PubMed |
| 35,830,292 | Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. | Blood Adv | 2022 | https://conductscience.org/library/papers/35830292 | PubMed |
| 34,079,772 | NHS-IL12, a Tumor-Targeting Immunocytokine. | Immunotargets Ther | 2021 | https://conductscience.org/library/papers/34079772 | PubMed |
| 30,185,656 | Induction of antiinflammatory purinergic signaling in activated human iNKT cells. | JCI Insight | 2018 | https://conductscience.org/library/papers/30185656 | PubMed |
| 30,131,389 | First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30131389 | PubMed |
| 21,646,050 | Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. | Clin Immunol | 2011 | https://conductscience.org/library/papers/21646050 | PubMed |
| 21,240,487 | Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. | Cancer Immunol Immunother | 2011 | https://conductscience.org/library/papers/21240487 | PubMed |
| 20,706,692 | Contribution of gut bacteria to liver pathobiology. | Gastroenterol Res Pract | 2010 | https://conductscience.org/library/papers/20706692 | PubMed |
| 20,034,047 | Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. | Hepatology | 2010 | https://conductscience.org/library/papers/20034047 | PubMed |
| 19,411,762 | Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. | J Clin Invest | 2009 | https://conductscience.org/library/papers/19411762 | PubMed |
| 17,710,228 | Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. | J Clin Invest | 2007 | https://conductscience.org/library/papers/17710228 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD1D | 912 | PubTator's text mining | https://conductscience.org/library/genes/912 | NCBI Gene |
| IFNG | 3,458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL10 | 3,586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL12B | 3,593 | PubTator's text mining | https://conductscience.org/library/genes/3593 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15123775
GET https://conductscience.org/api/papers/v1/15123775/authors